News und Analysen
![Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector
Waters Corporation (NYSE:WAT) today released the ACQUITY RDa™ Detector featuring SmartMS™, the company’s newest time-of-flight (TOF) mass spectrometer (MS) for small molecule analysis for
![Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer
Agilent Technologies Inc. (NYSE: A), today announced that Dr. Katharine (Kate) Knobil is joining Agilent as the company’s chief medical officer (CMO). The chief medical officer at Agilent is a
PerkinElmer Launches Comprehensive Solutions for Detecting SARS-CoV-2 Mutations
PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX®
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec
![Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection
Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in
![Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Neue Studie zeigt auf, dass mehr Auftragsforschungsinstitute Maßnahmen ergreifen, um dem dringenden Bedarf an schnelleren klinischen Studien gerecht zu werden
Auftragsforschungsinstitute machen bedeutende Fortschritte bei der Modernisierung und Verkürzung klinischer Studien, so die Ergebnisse der aktuellen Veeva Unified Clinical Operations Survey: Annual
![Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
Illumina, Inc.’s (NASDAQ: ILMN) NextSeq™ 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq™Dx which was approved previously
PerkinElmer Prices Offering of Senior Notes
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $400.0 million aggregate principal amount of 2.550%
![Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, Executive Vice President, Global Supply, at the
![New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials
Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO
![New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials
Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO
![U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer
The U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE: PFE) supplemental New Drug Application (sNDA) for LORBRENA® (lorlatinib), expanding the indication to include first-line
![Agilent Technologies Announces Pricing of $850 Million of Senior Notes](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Agilent Technologies Announces Pricing of $850 Million of Senior Notes
Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amount of $850 million. The
![Humana and the University of Houston Announce New Value-based Care Specialization Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana and the University of Houston Announce New Value-based Care Specialization Program
Today, Humana (NYSE: HUM) and the University of Houston announced the launch of a Value-based Care Specialization online program to support providers, academia and other business and industry
![Agilent Technologies Announces Proposed Offering of Senior Notes](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Agilent Technologies Announces Proposed Offering of Senior Notes
Agilent Technologies Inc. (NYSE:A) today announced it is offering, subject to market and other conditions, a series of senior notes under an automatic shelf registration statement on file with the
![Veeva Announces Fourth Quarter and Fiscal Year 2021 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Veeva Announces Fourth Quarter and Fiscal Year 2021 Results
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fourth quarter and fiscal year ended January
![Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
Agilent Technologies Inc. (NYSE: A), today announced it has entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of
![Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo
Agilent Technologies Inc. (NYSE: A) today announced that the recipient of the 2021 Darlene Solomon Award is Noemi Jiménez-Rojo, a postdoctoral fellow studying membrane biology, lipid diversity, and
![Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has
PerkinElmer to Present at Barclays Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Barclays Global Healthcare Conference on
![European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine
![EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiencyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for
![Humana Military Names Alefiyah Mesiwala, M.D., Chief Medical Officer](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Humana Military Names Alefiyah Mesiwala, M.D., Chief Medical Officer
Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today the appointment of Alefiyah Mesiwala, M.D., MPH, as Humana Military’s new Chief Medical Officer. Effective
![Mercy and Humana Team Up to Expand Access to Virtual Health Services and Coordinated Care: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Mercy and Humana Team Up to Expand Access to Virtual Health Services and Coordinated Care
Missouri-based Mercy and leading health and well-being company Humana Inc. (NYSE: HUM) have signed an agreement to expand patient access to virtual health resources as part of a broader, joint
![Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variantshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine